97 results on '"Puozzo, C."'
Search Results
2. Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients
3. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring
4. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours
5. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
6. Development of a sensitive liquid chromatography method coupled with a tandem mass spectrometric detection for the clinical analysis of vinflunine and 4-O-deacetyl vinflunine in blood, urine and faeces
7. A high performance liquid chromatography method for vinorelbine and 4- O-deacetyl vinorelbine: A decade of routine analysis in human blood
8. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients
9. Novel disease-specific behaviour of intravenous busulfan in children with thalassaemia undergoing haematopoietic stem cell transplantation requires a different approach to therapeutic drug monitoring: O395
10. Which bioequivalence study for a racemic drug? Application to milnacipran
11. Pharmacokinetics of milnacipran in renal impairment
12. Pharmacokinetics of milnacipran in liver impairment
13. Metabolism pathway of vinorelbine (Navelbine®) in human: Characterisation of the metabolites by HPLC–MS/MS
14. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours
15. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors
16. Clinical Trials in Paediatric Oncology
17. New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces
18. Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran
19. Metronomic Oral Vinorelbine in Patients with Recurrent Breast, Prostate or Non-Small Cell Lung Cancer: Optimal Dose-Finding Trial of the Hellenic Cooperative Oncology Group
20. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer.
21. Pharmacokinetics of milnacipran in comparison with other antidepressants.
22. 109 POSTER Metronomic oral vinorelbine: dose escalation study, pharmacokinetics and assessment of predictive biomarkers
23. P.1.011 Absence of interaction of milnacipran with the cytochrome P450 system — evidence from human volunteer studies
24. Reliable use of Navelbine oral based on pharmacokinetic (PK) bioequivalence
25. 560 Search for drug-drug interaction between oral vinorelbine (VRL) and capecitabine (CAP) in metastatic breast cancer (MBC) during a dose finding study.
26. Validated method for the determination of idazoxan in human plasma by liquid chromatography with tandem mass spectrometric detection
27. Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent
28. Comparative study of binding of an antiallergic substance to serum albumin and erythrocytes in man, in the dog and in the rat
29. Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat
30. Differences in the metabolism of epicainide in rats and man
31. Metabolism pathway of vinorelbine (Navelbine®) in human: Characterisation of the metabolites by HPLC–MS/MS
32. Oral versus intravenous vinorelbine: clinical safety profile
33. A simple and sensitive high-performance liquid chromatographic method for the determination of vinflunine and 4-O-deacetylvinflunine from human blood.
34. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
35. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
36. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
37. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer.
38. Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors.
39. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
40. Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management.
41. Can similar oral blood exposures between studies result in a different bioavailability?
42. Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran.
43. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine.
44. Oral versus intravenous vinorelbine: clinical safety profile.
45. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.
46. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
47. Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection.
48. Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics.
49. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
50. Pharmacology and pharmacokinetics of milnacipran.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.